Key facts
- This page summarizes Andrew Lo's Form 4 filing for Roivant Sciences Ltd. (ROIV).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Sep 2022, 21:53.
Andrew Lo - 15 Sep 2022 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- Director
- Issuer ticker
- ROIV
- Reported as of
- 15 Sep 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Sep 2022, 21:53:32 UTC
- Prior SEC filing
- 24 Jun 2022
- Next SEC filing
- 05 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jo Chen, as Attorney-in-Fact for Andrew Lo
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew Lo filed Form 4 for Roivant Sciences Ltd. (ROIV) on 19 Sep 2022.
Change
- Previous filing in this sequence was filed on 24 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
transaction
Common Shares
Award
- Transaction value
- $0
- Shares
- +52,142
- Change %
- Price
- $0.000000
- Shares after
- 52,142
- Date
- 15 Sep 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +71,850
- Change %
- Price
- $0.000000
- Shares after
- 71,850
- Date
- 15 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 71,850
- Exercise price
- $3.50
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date.
Footnote F2
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date.